Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de fármacos antifactor de necrosis tumoral α en la enfermedad inflamatoria intestinal (2013)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Domènech, 2002, Recomendaciones para el uso de infliximab (Remicade®) en la enfermedad de Crohn. GETECCU 2001, Gastroenterol Hepatol, 25, 162, 10.1016/S0210-5705(02)79012-2
Domènech, 2005, Recomendaciones GETECCU-2005 para el uso de infliximab (Remicade®) en la enfermedad inflamatoria intestinal, Gastroenterol Hepatol, 28, 126, 10.1157/13072012
Obrador, 2003, Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU).Guía de consenso sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab, Gastroenterol Hepatol, 26, 29, 10.1157/13042212
López-San Román, 2006, Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Recomendaciones sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Actualización 2006, Gastroenterol Hepatol, 29, 81, 10.1157/13083915
Cabriada, 2008, Recomendaciones de actuación en pacientes con enfermedad de Crohn que empiezan tratamiento con adalimumab:una guía rápida, Gastroenterol Hepatol, 31, 693, 10.1016/S0210-5705(08)75817-5
Rutgeerts, 2004, Optimizing anti-TNF treatment in inflammatory bowel disease, Gastroenterology, 126, 1593, 10.1053/j.gastro.2004.02.070
Targan, 2007, Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial, Gastroenterology, 132, 1672, 10.1053/j.gastro.2007.03.024
Sandborn, 2012, Ustekinumab induction and maintenance therapy in refractory Crohn's disease, N Engl J Med, 367, 1519, 10.1056/NEJMoa1203572
Dignass, 2010, The second European evidence based consensus on the diagnosis and management of Crohn's disease: current management, J Crohns Colitis, 4, 28, 10.1016/j.crohns.2009.12.002
van Assche, 2010, The second European evidence based Consensus on the diagnosis and management of Crohn's disease: special situations, J Crohns Colitis, 4, 63, 10.1016/j.crohns.2009.09.009
Dignass, 2012, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 1: definitions and diagnosis, J Crohns Colitis, 6, 965, 10.1016/j.crohns.2012.09.003
Dignass, 2012, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: current management, J Crohns Colitis, 6, 991, 10.1016/j.crohns.2012.09.002
d’Haens, 2011, The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose and how to predict response?, Am J Gastroenterol, 106, 199, 10.1038/ajg.2010.392
Orlando, 2011, The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease, Dig Liv Dis, 43, 1, 10.1016/j.dld.2010.07.010
Targan, 1997, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group, N Engl J Med, 337, 1029, 10.1056/NEJM199710093371502
Hanauer, 2006, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial, Gastroenterology, 130, 323, 10.1053/j.gastro.2005.11.030
Hanauer, 2002, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, Lancet, 359, 1541, 10.1016/S0140-6736(02)08512-4
Colombel, 2007, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial, Gastroenterology, 132, 52, 10.1053/j.gastro.2006.11.041
Peyrin-Biroulet, 2008, Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo controlled trials, Clin Gastroenterol Hepatol, 6, 644, 10.1016/j.cgh.2008.03.014
Behm, 2008, Tumor necrosis factor alpha antibody for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, 1, CD006893
Chaparro, 2011, Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose «escalation» in patients losing response, J Clin Gastroenterol, 45, 113, 10.1097/MCG.0b013e3181ebaef9
Fortea-Ormaechea, 2011, Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease, The Madrid experience Gastroenterol Hepatol, 34, 443, 10.1016/j.gastrohep.2011.04.001
González-Lama, 2008, Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response, Gastroenterol Hepatol, 31, 421, 10.1157/13125587
Panaccione, 2010, Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease, Aliment Pharmacol Ther, 31, 1296, 10.1111/j.1365-2036.2010.04304.x
Schnitzler, 2009, Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort, Gut, 58, 492, 10.1136/gut.2008.155812
Sandborn, 2007, Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial (GAIN), Ann Intern Med, 146, 829, 10.7326/0003-4819-146-12-200706190-00159
Panaccione, 2008, Adalimumab maintains long-term remission in moderately to severely active Crohn's disease after IFX failure: 1-year follow-up of GAIN trial, Gastroenterology, 134, S133
d’Haens, 2008, Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, Lancet, 371, 660, 10.1016/S0140-6736(08)60304-9
Baert, 2010, Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease, Gastroenterology, 138, 463, 10.1053/j.gastro.2009.09.056
Schreiber, 2007, Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM, Gastroenterology, 132, A985, 10.1053/j.gastro.2007.03.068
Lionetti, 2003, Response to infliximab is related to disease duration in paediatric Crohn's disease, Aliment Pharmacol Ther, 18, 425, 10.1046/j.1365-2036.2003.01672.x
Kugathasan, 2000, Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease, Am J Gastroenterol, 95, 3189, 10.1111/j.1572-0241.2000.03263.x
Beaugerie, 2006, Predictors of Crohn's disease, Gastroenterology, 130, 650, 10.1053/j.gastro.2005.12.019
Loly, 2008, Predictors of severe Crohn's disease, Scand J Gastroenterol, 43, 948, 10.1080/00365520801957149
Seksik, 2007, Validation of predictors of 5-year disabling CD in a population-based cohort from Olmsted County, Minnesota 1983-1996, Gastroenterology, 132
Vermeire, 2007, Review article: altering the natural history of Crohn's disease-evidence for and against current therapies, Aliment Pharmacol Ther, 25, 3, 10.1111/j.1365-2036.2006.03134.x
Lémann, 2006, Infliximab plus azathioprine for steroid dependent Crohn's disease patients: a randomized placebo-controlled trial, Gastroenterology, 130, 1054, 10.1053/j.gastro.2006.02.014
Mantzaris, 2004, A prospective, randomized trial of infliximab (IFX) and azathioprine (AZA) for the induction and maintenance of remission of steroid-dependent Crohn's disease, Gastroenterology, 126, A437
Costes, 2008, Long term follow up of a cohort of steroid-dependent Crohn's disease patients included in a randomized trial evaluating short term infliximab combined with azathioprine, Gastroenterology, 134, A134, 10.1016/S0016-5085(08)60621-6
Rutgeerts, 2005, Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 353, 2462, 10.1056/NEJMoa050516
Present, 1999, Infliximab for the treatment of fistulas in patients with Crohn's disease, N Engl J Med, 340, 1398, 10.1056/NEJM199905063401804
Sands, 2004, Infliximab maintenance therapy for fistulizing Crohn's disease, N Engl J Med, 350, 876, 10.1056/NEJMoa030815
Colombel, 2009, Adalimumab for the treatment of fistulas in patients with Crohn's disease, Gut, 58, 940, 10.1136/gut.2008.159251
Hinojosa, 2007, Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial, Aliment Pharmacol Ther, 25, 409, 10.1111/j.1365-2036.2006.03232.x
Regueiro, 2003, Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement, Inflamm Bowel Dis, 9, 98, 10.1097/00054725-200303000-00003
Topstad, 2003, Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulising anorectal Crohn's disease. A single center experience, Dis Colon Rectum, 46, 577, 10.1007/s10350-004-6611-4
Hyder, 2006, Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment, Dis Colon Rectum, 49, 1837, 10.1007/s10350-006-0656-5
Gaertner, 2007, Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?, Dis Colon Rectum, 50, 1754, 10.1007/s10350-007-9077-3
West, 2004, Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study, Aliment Pharmacol Ther, 20, 1329, 10.1111/j.1365-2036.2004.02247.x
Domènech, 2005, Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?, Aliment Pharmacol Ther, 22, 1107, 10.1111/j.1365-2036.2005.02670.x
van Assche, 2003, Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease, Am J Gastroenterol, 98, 332, 10.1016/S0002-9270(02)05909-9
Bell, 2003, Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging, Aliment Pharmacol Ther, 17, 387, 10.1046/j.1365-2036.2003.01427.x
Ng, 2009, Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas, Am J Gastroenterol, 104, 2973, 10.1038/ajg.2009.509
Spradlin, 2008, A randomized prospective trial of endoscopic ultrasound to guide combination medical and surgical treatment for Crohn's perianal fistulas, Am J Gastroenterol, 103, 2527, 10.1111/j.1572-0241.2008.02063.x
Poggioli, 2005, Local injection of infliximab for the treatment of perianal Crohn's disease, Dis Colon Rectum, 48, 768, 10.1007/s10350-004-0832-4
Asteria, 2006, Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study, Scand J Gastroenterol, 41, 1064, 10.1080/00365520600609941
Andreani, 2007, Rectovaginal fistula in Crohn's disease, Dis Colon Rectum, 50, 2215, 10.1007/s10350-007-9057-7
de la Poza, 2012, Genital fistulas in female Crohn's disease patients: clinical characteristics and response to therapy, J Crohns Colitis, 3, 276, 10.1016/j.crohns.2011.08.015
Miehsler, 2004, Infliximab: lack of efficacy on perforating complications in Crohn's disease, Inflamm Bowel Dis, 10, 36, 10.1097/00054725-200401000-00006
Parsi, 2004, Type of fistula determines response to infliximab in patients with fistulous Crohn's disease, Am J Gastroenterol, 99, 445, 10.1111/j.1572-0241.2004.04083.x
Sorrentino, 2007, Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease, Arch Intern Med, 167, 1804, 10.1001/archinte.167.16.1804
Sorrentino, 2010, Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease, Clin Gastroenterol Hepatol, 8, 591, 10.1016/j.cgh.2010.01.016
Regueiro, 2009, Infliximab prevents Crohn's disease recurrence after ileal resection, Gastroenterology, 136, 441, 10.1053/j.gastro.2008.10.051
Yoshida, 2012, Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: A 3-year prospective randomized open trial, Inflamm Bowel Dis, 18, 1617, 10.1002/ibd.21928
De Cruz, 2012, Adalimumab prevents post-operative Crohn's disease recurrence and is superior to thiopurines: Early results from the prospective POCER study, J Crohns Colitis, 6, S146, 10.1016/S1873-9946(12)60361-4
Papamichael, 2012, Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: A prospective, two-year, single center, pilot study, J Crohns Colitis, 6, 924, 10.1016/j.crohns.2012.02.012
Aguas, 2012, Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients, World J Gastroenterol, 18, 4391, 10.3748/wjg.v18.i32.4391
d’Haens, 2008, Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial, Gastroenterology, 135, 1123, 10.1053/j.gastro.2008.07.010
Mañosa, 2012, Azatioprina frente a azatioprina con metronidazol para la prevención de la recurrencia endoscópica posquirúrgica en la enfermedad de Crohn: estudio aleatorizado,doble ciego y controlado con placebo, Gastroenterol Hepatol, 35, 148
Lawson, 2006, Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, 3, CD005112
Gisbert, 2007, Systematic review:Infliximab therapy in ulcerative colitis, Aliment Pharmacol Ther, 25, 19, 10.1111/j.1365-2036.2006.03131.x
Ferrante, 2008, Long-term outcome after infliximab for refractory ulcerative colitis, J Crohns Colitis, 2, 219, 10.1016/j.crohns.2008.03.004
Sandborn, 2009, Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab, Gastroenterology, 137, 1250, 10.1053/j.gastro.2009.06.061
Reinisch, 2011, Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial, Gut, 60, 780, 10.1136/gut.2010.221127
Reinisch, 2011, 52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppresants, J Crohns Colitis, 5, S10
Sandborn, 2012, Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 142, 257, 10.1053/j.gastro.2011.10.032
Gies, 2010, Treatment of ulcerative colitis with adalimumab or infliximab:long-term follow-up of a single-centre cohort, Aliment Pharmacol Ther, 32, 522, 10.1111/j.1365-2036.2010.04380.x
Ferrante, 2011, Efficacy of adalimumab in patients with ulcerative colitis: restoration of serum levels after dose escalation results in a better long-term outcome, Gut, 60, 72
Taxonera, 2011, Adalimumab induction and maintenanace therapy for patients with ulcerative colitis previously treated with infliximab, Aliment Pharmacol Ther, 33, 340, 10.1111/j.1365-2036.2010.04531.x
García-Bosch, 2012, Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome, J Crohns Colitis, 10.1016/j.crohns.2012.10.004
Järnerot, 2005, Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo controlled study, Gastroenterology, 128, 1805, 10.1053/j.gastro.2005.03.003
Gustavsson, 2010, Clinical trial: colectomy after rescue therapy in ulcerative colitis –3-year follow-up of the Swedish-Danish controlled infliximab study, Aliment Pharmacol Ther, 32, 984, 10.1111/j.1365-2036.2010.04435.x
Laharie, 2012, Ciclosporine versus infliximab in acute severe ulcerative colitis refractory to intravenous steroids: a randomized study, Lancet, 380, 1909, 10.1016/S0140-6736(12)61084-8
Maser, 2008, Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis, Clin Gastroenterol Hepatol, 6, 1112, 10.1016/j.cgh.2008.04.035
Mañosa, 2009, Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis, Digestion, 80, 30, 10.1159/000212075
Leblanc, 2011, Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis, Am J Gastroenterol, 106, 771, 10.1038/ajg.2011.62
Chaparro, 2012, Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study, Aliment Pharmacol Ther, 35, 275, 10.1111/j.1365-2036.2011.04934.x
Armuzzi, 2012, Infliximab in steroid-dependent ulcerative colitis: efficacy and predictors of clinical and endoscopic remission, Gastroenterology, 142, S1, 10.1016/S0016-5085(12)60770-7
Barreiro-de Acosta, 2009, Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis, J Crohns Colitis, 3, 271, 10.1016/j.crohns.2009.06.003
Barreiro-Acosta, 2012, Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study, Inflamm Bowel Dis, 18, 812, 10.1002/ibd.21821
Ferrante, 2012, Patients with refractory pouchitis receiving adalimumab may avoid permanent ileostomy, J Crohns Colitis, 6, S114, 10.1016/S1873-9946(12)60282-7
Barreiro-de Acosta, 2012, Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series, Eur J Gastroenterol Hepatol, 24, 756, 10.1097/MEG.0b013e3283525a7b
Braun, 2008, Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period, Arthritis Rheum, 59, 1270, 10.1002/art.24001
van der Heijde, 2009, Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial, Ann Rheum Dis, 68, 922, 10.1136/ard.2007.087270
Rispo, 2005, Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease, Scand J Rheumatol, 34, 387, 10.1080/03009740510026698
Generini, 2004, Infliximab in spondyloarthropathy associated with Crohn‘s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations, Ann Rheum Dis, 63, 1664, 10.1136/ard.2003.012450
Brooklyn, 2006, Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial, Gut, 55, 505, 10.1136/gut.2005.074815
Regueiro, 2003, Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease, Am J Gastroenterol, 98, 1821, 10.1111/j.1572-0241.2003.07581.x
Cariñanos, 2011, Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease, Inflamm Bowel Dis, 17, 153, 10.1002/ibd.21723
Suhler, 2009, Infliximab therapy for refractory uveitis: 2-year results of a prospective trial, Arch Ophthalmol, 127, 819, 10.1001/archophthalmol.2009.141
Doctor, 2010, Infliximab for the treatment of refractory scleritis, Br J Ophthalmol, 94, 579, 10.1136/bjo.2008.150961
Mahadevan, 2011, The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: Pregnancy and Pediatrics, Am J Gastroenterol, 106, 214, 10.1038/ajg.2010.464
Hyams, 2007, Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children, Gastroenterology, 132, 863, 10.1053/j.gastro.2006.12.003
Hyams, 2012, Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis, Clin Gastroenterol Hepatol, 10, 391, 10.1016/j.cgh.2011.11.026
Hyams, 2012, Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children, Gastroenterology, 143, 365, 10.1053/j.gastro.2012.04.046
Faubion, 2001, The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study, Gastroenterology, 121, 255, 10.1053/gast.2001.26279
Munkholm, 1994, Frequency of glucocorticoid resistance and dependency in Crohn‘s disease, Gut, 35, 360, 10.1136/gut.35.3.360
Ho, 2006, The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort, Aliment Pharmacol Ther, 24, 319, 10.1111/j.1365-2036.2006.02974.x
Lichtenstein, 2012, Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry, Am J Gastroenterol, 107, 1409, 10.1038/ajg.2012.218
Toruner, 2008, Risk factors for opportunistic infections in patients with inflammatory bowel disease, Gastroenterology, 134, 929, 10.1053/j.gastro.2008.01.012
Ferrante, 2009, Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease), Curr Gastroenterol Reports, 11, 504, 10.1007/s11894-009-0076-5
Allez, 2010, The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease alter failure of two other anti-TNF antibodies, Aliment Pharmacol Ther, 31, 92, 10.1111/j.1365-2036.2009.04130.x
Rutgeerts, 2006, Scheduled maintenance treatment with Infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease, Gastrointest Endosc, 63, 433, 10.1016/j.gie.2005.08.011
Lichtenstein, 2004, Remission in patients with Crohn‘s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries, Am J Gastroenterol, 99, 91, 10.1046/j.1572-0241.2003.04010.x
Lichtenstein, 2002, Infliximab improves quality of life in patients with Crohn‘s disease, Inflamm Bowel Dis, 8, 237, 10.1097/00054725-200207000-00001
Rutgeerts, 2004, Comparation of scheduled and episodic treatment strategies of infliximab in Crohn's disease, Gastroenterology, 126, 402, 10.1053/j.gastro.2003.11.014
Hanauer, 2004, Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease, Clin Gastroenterol Hepatol, 2, 542, 10.1016/S1542-3565(04)00238-1
Baert, 2003, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn‘s disease, N Engl J Med, 348, 601, 10.1056/NEJMoa020888
Rutgeerts, 1999, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease, Gastroenterology, 117, 761, 10.1016/S0016-5085(99)70332-X
Reinisch, 2012, Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies, Inflamm Bowel Dis, 18, 201, 10.1002/ibd.21697
Sandborn, 2007, Adalimumab for maintenance treatment of Crohn‘s disease: results of the CLASSIC II trial, Gut, 56, 1232, 10.1136/gut.2006.106781
Gisbert, 2009, Loss of response and requirement of Infliximab dose intensification in Crohn's disease: a review, Am J Gastroenterol, 104, 760, 10.1038/ajg.2008.88
Billioud, 2011, Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review, Am J Gastroenterol, 106, 674, 10.1038/ajg.2011.60
Ordas, 2012, Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms, Clin Pharmacol Ther, 91, 635, 10.1038/clpt.2011.328
Maser, 2006, Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn‘s disease, Clin Gastroenterol Hepatol, 4, 1248, 10.1016/j.cgh.2006.06.025
Vermeire, 2007, Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn‘s disease, Gut, 56, 1226, 10.1136/gut.2006.099978
Karmiris, 2009, Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn‘s disease, Gastroenterology, 137, 1628, 10.1053/j.gastro.2009.07.062
Chaparro, 2012, Long-term durability of response to adalimumab in Crohn‘s disease, Inflamm Bowel Dis, 18, 685, 10.1002/ibd.21758
Katz, 2012, Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response, Inflamm Bowel Dis, 18, 2026, 10.1002/ibd.22902
Kopylov, 2011, The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab, Aliment Pharmacol Ther, 33, 349, 10.1111/j.1365-2036.2010.04523.x
Sandborn, 2008, Current directions in IBD therapy: what goals are feasible with biological modifiers?, Gastroenterology, 135, 1442, 10.1053/j.gastro.2008.09.053
Chaparro, 2011, Effectiveness of a dose «de-escalation» strategy with anti-TNF drugs in patients with Crohn's disease (CD), J Crohns Colitis, 5, S103
Sprakes, 2011, Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn‘s disease: A single centre experience, J Crohns Colitis, 5, 324, 10.1016/j.crohns.2011.02.007
Chaparro, 2012, Effectiveness of infliximab after adalimumab failure in Crohn's disease, World J Gastroenterol, 18, 5219
Rutgeerts, 2010, Predicting the response to infliximab from trough serum levels, Gut, 59, 7, 10.1136/gut.2009.191411
Ordás, 2012, Therapeutic drug monitoring of tumor necrosis factor antagonist in inflammatory bowel disease, Clin Gastroenterol Hepatol, 10, 1079, 10.1016/j.cgh.2012.06.032
Pariente, 2012, Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease, Inflamm Bowel Dis, 18, 1199, 10.1002/ibd.21839
Louis, 2012, Maintenance of remission among patients with Crohn‘s disease on antimetabolite therapy after infliximab therapy is stopped, Gastroenterology, 142, 63, 10.1053/j.gastro.2011.09.034
Domènech, 2010, Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen, J Clin Gastroenterol, 44, 34, 10.1097/MCG.0b013e3181962dfa
Hommes, 2006, Guidelines for treatment with infliximab for Crohn's disease, Neth J Med, 64, 219
Lichstenstein, 2009, Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials, Aliment Pharmacol Ther, 30, 210, 10.1111/j.1365-2036.2009.04027.x
Colombel, 2010, Infliximab, azathioprine, or combination therapy for Crohn's disease, N Engl J Med, 362, 1383, 10.1056/NEJMoa0904492
Gomollón, 2010, ¿Es necesario asociar inmunomoduladores al tratamiento biológico en la enfermedad inflamatoria intestinal?, Gastroenterol Hepatol, 33, 43, 10.1016/j.gastrohep.2009.03.008
Panaccione, 2011, Infliximab, azathioprine,or infliximab + azathioprine for treatment of moderate to severe UC SUCCESS trial, J Crohns Colitis, 5, S8
Feagan, 2008, A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease, Gastroenterology, 135, 294, 10.1053/j.gastro.2008.05.061
Sokol, 2010, Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy, Gut, 59, 1363, 10.1136/gut.2010.212712
Reenaers, 2012, Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?, Aliment Pharmacol Ther, 36, 1040, 10.1111/apt.12076
Oussalah, 2010, Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy, Am J Gastroenterol, 105, 1142, 10.1038/ajg.2010.158
Mould, 2010, Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development, Biodurgs, 24, 23, 10.2165/11530560-000000000-00000
Guerra, 2011, Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease, Curr Drug Metab, 12, 594, 10.2174/138920011795713689
Cassinotti, 2009, Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review, Inflamm Bowel Dis, 15, 1264, 10.1002/ibd.20899
van Assche, 2008, Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial, Gastroenterology, 134, 1861, 10.1053/j.gastro.2008.03.004
Lichtenstein, 2006, Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry, Clin Gastroenterol Hepatol, 4, 621, 10.1016/j.cgh.2006.03.002
Cottone, 2011, Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease, Clin Gastroenterol Hepatol, 9, 30, 10.1016/j.cgh.2010.09.026
Loras, 2010, Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy, Gut, 59, 1340, 10.1136/gut.2010.208413
Beaugerie, 2009, Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, Lancet, 374, 1617, 10.1016/S0140-6736(09)61302-7
Peyrin-Biroulet, 2011, Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease, Gastroenterology, 141, 1621, 10.1053/j.gastro.2011.06.050
Siegel, 2012, Adverse events do not outweight benefits of combination therapy for Crohn's disease in a decision analytic model, Clin Gastroenterol Hepatol, 10, 46, 10.1016/j.cgh.2011.09.017
Loftus, 2011, Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease, Inflamm Bowel Dis, 17, 127, 10.1002/ibd.21341
Dixon, 2012, Inmediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis, Ann Rheum Dis, 71, 1128, 10.1136/annrheumdis-2011-200702
Aubin, 2012, The complexity of adverse side-effects to biological agents, J Crohns Colitis, 10.1016/j.crohns.2012.06.024
Fallahi-Sichani, 2012, Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability, J Immunol, 188, 3169, 10.4049/jimmunol.1103298
Singh, 2011, Adverse effects of biologics: a network meta-analysis and Cochrane overview, Cochrane Database Syst Rev, 2, CD008794
Busquets, 2011, Revisión sistemática: eficacia y seguridad del tratamiento anti-TNF en pacientes ancianos, Reumatol Clín, 7, 104, 10.1016/j.reuma.2010.02.001
Dixon, 2011, Is Anti-TNF therapy safer than previously thought?, JAMA, 306, 2380, 10.1001/jama.2011.1705
Burmester, 2009, Adalimumab safety and mortality rates from global trials of six immune-mediated inflammatory diseases, Ann Rheum Dis, 68, 1863, 10.1136/ard.2008.102103
Burmester, 2012, Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiophatic arthritis, ankylosisng spondylitis, psoriatic arthritis, psoriasis and Crohn's disease, Ann Rheum Dis, 10.1136/annrheumdis-2012-eular.3077
Lichtenstein, 2012, A pooled analysis of infections, malignancy and mortality in infliximab-and immunomodulator-treated adult patients with inflammatory bowel disease, Am J Gastroenterol, 107, 1051, 10.1038/ajg.2012.89
Viget, 2008, Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis, Gut, 57, 549, 10.1136/gut.2006.114660
Ananthakrishnan, 2013, Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases, J Crohns Colitis, 7, 107, 10.1016/j.crohns.2012.02.015
Grijalva, 2011, Initiation of tumor necrosis factor-alfa antagonists and the risk of hospitalization for infection in patients with autoinmune diseases, JAMA, 306, 2331, 10.1001/jama.2011.1692
Beaugerie, 2012, Inflammatory Bowel Disease therapies and cancer risk: where are we and where are we going?, Gut, 61, 476, 10.1136/gutjnl-2011-301133
Deepak, 2013, T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study, Am J Gastroenterol, 108, 99, 10.1038/ajg.2012.334
Siegel, 2009, Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease. A meta-analysis, Clin Gastroenterol Hepatol, 7, 874, 10.1016/j.cgh.2009.01.004
Bewtra, 2012, Lymphoma in inflammatory bowel disease and treatment decisions, Am J Gastroenterol, 107, 964, 10.1038/ajg.2011.479
Kotlyar, 2010, Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality, Am J Gastroenterol, 105, 2299, 10.1038/ajg.2010.213
Stallman, 2010, Adverse effects of biologics used for treating IBD, Best Pract Res Clin Gastroenterol, 24, 167, 10.1016/j.bpg.2010.01.002
Miehsler, 2010, Austrian Society of Gastroenterology and Hepatology. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease, J Crohns Colitis, 4, 221, 10.1016/j.crohns.2009.12.001
van Assche, 2011, Immunogenicity of anti-TNF antibodies. Has the veil been lifted?, Gut, 60, 285, 10.1136/gut.2009.199687
Collamer, 2010, Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis, Semin Arthritis Rheum, 40, 233, 10.1016/j.semarthrit.2010.04.003
Guerra, 2012, Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases J Crohns Colitis, 6, 518
Denadai, 2012, Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases, J Crohns Colitis, 10.1016/j.crohns.2012.08.007
Cleynen, 2012, Paradoxical inflammation induced by anti-TNF agents in patients with IBD, Nat Rev Gastroenterol Hepatol, 9, 496, 10.1038/nrgastro.2012.125
Ali, 2012, Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease, World J Gastroenterol, 18, 197, 10.3748/wjg.v18.i3.197
Casellas, 2012, Restoration of quality of life of patients with inflammatory bowel disease alter one year with antiTNFα treatment, J Crohns Colitis, 6, 881, 10.1016/j.crohns.2012.01.019
Bongartz, 2011, Can treatment of chronic inflammatory diseases reduce the risk of diabetes mellitus?, JAMA, 305, 2573, 10.1001/jama.2011.884
Rahier, 2009, European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, J Crohns Colitis, 3, 47, 10.1016/j.crohns.2009.02.010
Gisbert, 2012, Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease, Am J Gastroenterol, 107, 1460, 10.1038/ajg.2012.79
Zhang, 2012, Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases, JAMA, 308, 43, 10.1001/jama.2012.7304
Rahier, 2010, Vaccinations in patients with immune-mediated inflammatory diseases, Rheumatology, 49, 1815, 10.1093/rheumatology/keq183
Wasan, 2010, A practical guide to vaccinating the inflammatory bowel disease patient, Am J Gastroenterol, 105, 1231, 10.1038/ajg.2009.733
Ledingham, 2005, British Society for Rheumatology Standards, Guidelines and Audit Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001), Rheumatology (Oxford), 44, 157, 10.1093/rheumatology/keh464
Nathan, 2006, Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach, J Gastroenterol Hepatol, 21, 1366, 10.1111/j.1440-1746.2006.04559.x
Calabrese, 2004, Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection, Ann Rheum Dis, 63, S18
Schnitzler, 2011, Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy, Inflamm Bowel Dis, 17, 1846, 10.1002/ibd.21583
van der Woude, 2012, European evidence-based consensus on reproduction in inflammatory bowel disease, J Crohns Colitis, 4, 493, 10.1016/j.crohns.2010.07.004
Casanova, 2012, Safety of immunomodulators and anti-TNF drugs for the treatment of inflammatory bowel disease during pregnancy, Am J Gastroenterol
Gisbert, 2010, Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding, Inflamm Bowel Dis, 16, 881, 10.1002/ibd.21154
Chaparro, 2011, Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease, Curr Pharm Biotechnol, 12, 765, 10.2174/138920111795470903
Mahadevan, 2012, Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease, Clin Gastroenterol Hepatol
Cheent, 2010, Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease, J Crohns Colitis, 4, 603, 10.1016/j.crohns.2010.05.001
Mahadevan, 2012, PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy, Gastroenterology, 142, S149, 10.1016/S0016-5085(12)60561-7
Habal, 2012, Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient, Aliment Pharmacol Ther, 35, 501, 10.1111/j.1365-2036.2011.04967.x
Ben-Horin, 2011, Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease, J Crohns Colitis, 5, 555, 10.1016/j.crohns.2011.05.006
Fritzsche, 2012, Infliximab and adalimumab use during breastfeeding, J Clin Gastroenterol, 46, 718, 10.1097/MCG.0b013e31825f2807
Bernick, 2012, Drug transfer to the fetus and to the breastfeeding infant: what do we know?, Curr Drug Deliv, 9, 350, 10.2174/156720112801323116
Stengel, 2008, Is infliximab safe to use while breastfeeding?, World J Gastroenterol, 14, 3085, 10.3748/wjg.14.3085
Louis, 2007, Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study, Acta Gastroenterol Belg, 70, 15
Sempere, 2010, Recomendaciones para la vacunación de adultos con enfermedad inflamatoria intestinal, 19
Beigel, 2011, Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease, Inflamm Bowel Dis, 17, 91, 10.1002/ibd.21362
Esteve, 2011, Inflammatory bowel disease in travelers: choosing the right vaccines and check-ups, World J Gastroenterol, 17, 2708, 10.3748/wjg.v17.i22.2708
Gisbert, 2011, Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease, Aliment Pharmacol Ther, 33, 619, 10.1111/j.1365-2036.2010.04570.x
Bermejo, 2012, How frequent are conversions of tuberculosis (TBC) screening tests among inflammatory bowel disease (IBD) patients under anti-TNF treatment?, J Crohns Colitis, 6, S76, 10.1016/S1873-9946(12)60187-1